Hub : Traits :

Angina

49 significantly associated models · 16 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 109098737 110517617 3 1 3.3e-12 3.3e-12 2.2e-01 97 SORT1
2 1 222133118 223529093 1 1 7.2e-08 7.8e-07 5.9e-01 99 RP11-378J18.8
3 6 12020241 13990267 2 1 2.3e-08 2.5e-08 1.0e+00 100 RP1-257A7.5
4 6 133961374 134468561 1 1 1.6e-09 9.0e-08 7.3e-01 100 TCF21
5 6 160071844 161571560 2 2 9.0e-08 5.2e-16 1.7e-08 52 SLC22A1 SLC22A3
6 9 21303958 22819407 2 2 2.2e-22 1.2e-34 1.6e-14 61 CDKN2B CDKN2B-AS1
7 15 78360691 79802863 2 2 9.8e-11 5.7e-10 2.7e-01 97 ADAMTS7
8 15 90718541 92135418 2 1 1.3e-11 1.4e-08 4.3e-01 98 FES
9 17 47119135 47685050 1 1 8.0e-08 2.3e-09 8.5e-03 81 ZNF652

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder (2018) 1.73 1 0 0.0 0.00 1.0e+00 FES
Bipolar Disorder or Schizophrenia 3.18 1 1 2.2 0.00 1.0e+00 FES
Neuroticism (Nagel 2018) 1.33 2 0 0.0 0.00 1.0e+00 FES SLC22A1
Schizophrenia (2018) 2.96 1 1 2.2 0.00 1.0e+00 FES
Worry (Nagel 2018) 0.95 1 0 0.0 0.00 1.0e+00 SLC22A1
Reaction Time 1.31 1 0 0.0 0.00 1.0e+00 ZNF652
Breast Cancer 2.52 3 0 0.0 0.00 1.0e+00 CDKN2B CDKN2B-AS1 FES
Age at First Birth 1.68 1 0 0.0 0.00 1.0e+00 ZNF652
Coronary Artery Disease (CAD) 28.57 6 4 8.9 0.99 1.4e-05 ADAMTS7 CDKN2B CDKN2B-AS1 RP1-257A7.5 SLC22A3 TCF21
HDL Cholesterol 2.13 1 1 2.2 0.00 1.0e+00 SORT1
LDL Cholesterol 43.35 1 1 2.2 0.00 1.0e+00 SORT1
Schizophrenia (2014) 3.01 1 1 2.2 0.00 1.0e+00 FES
Triglycerides 1.61 1 0 0.0 0.00 1.0e+00 ZNF652
Type 2 Diabetes (T2D) (2012) 3.21 1 0 0.0 0.00 1.0e+00 CDKN2B
Blood Eosinophil Count 2.19 1 1 2.2 0.00 1.0e+00 ZNF652
Blood Platelet Count 0.80 3 1 2.2 0.97 3.2e-02 ADAMTS7 CDKN2B SLC22A3
Blood Red Count 0.63 4 0 0.0 0.27 7.3e-01 FES RP1-257A7.5 TCF21 ZNF652
Blood White Count 1.20 3 1 2.2 0.00 1.0e+00 CDKN2B FES ZNF652
Heel T-Score 0.33 1 0 0.0 0.00 1.0e+00 SORT1
BMI 0.94 2 0 0.0 0.00 1.0e+00 SLC22A3 ZNF652
Height 1.26 4 4 8.9 -0.91 9.0e-02 FES SLC22A3 SORT1 ZNF652
Waist Hip Ratio (WHR) 2.13 2 1 2.2 0.00 1.0e+00 ADAMTS7 SLC22A3
Systolic Blood Pressure 7.01 7 4 8.9 0.53 2.2e-01 ADAMTS7 FES RP1-257A7.5 SLC22A1 SLC22A3 TCF21 ZNF652
Smoking Status 3.01 3 0 0.0 0.00 1.0e+00 FES SORT1 ZNF652
Allergy or Eczema 2.47 2 1 2.2 0.00 1.0e+00 FES ZNF652
Cardiovascular Disease 10.99 6 5 11.1 0.95 3.8e-03 FES SLC22A1 SLC22A3 SORT1 TCF21 ZNF652
Respiratory disease 3.20 2 1 2.2 0.00 1.0e+00 FES ZNF652
Type 2 Diabetes (T2D) (2018) 1.38 1 0 0.0 0.00 1.0e+00 SLC22A3
Lung FEV1/FVC ratio 2.05 4 1 2.2 0.58 4.2e-01 RP11-378J18.8 SORT1 TCF21 ZNF652
Lung FVC 1.02 1 1 2.2 0.00 1.0e+00 TCF21
Neuroticism 1.28 1 0 0.0 0.00 1.0e+00 SLC22A1
Hair Pigment 0.49 4 3 6.7 -0.80 2.0e-01 ADAMTS7 CDKN2B CDKN2B-AS1 FES
Hand grip strength (left) 1.73 2 1 2.2 0.00 1.0e+00 FES RP1-257A7.5
Number of treatments/medications taken 5.24 3 2 4.4 0.00 1.0e+00 FES SORT1 ZNF652
Sensitivity / hurt feelings 1.85 1 1 2.2 0.00 1.0e+00 FES
Systolic blood pressure, automated reading 5.50 2 1 2.2 0.00 1.0e+00 FES RP1-257A7.5
Medication: Metformin 1.63 1 0 0.0 0.00 1.0e+00 CDKN2B
Pack years adult smoking proportion 7.44 1 1 2.2 0.00 1.0e+00 ADAMTS7
Impedance of leg (right) 2.60 2 2 4.4 0.00 1.0e+00 FES ZNF652
Leg fat-free mass (left) 1.05 2 0 0.0 0.00 1.0e+00 FES SLC22A3
Trunk fat percentage 1.19 1 0 0.0 0.00 1.0e+00 SLC22A3
Hand grip strength (right) 1.20 1 0 0.0 0.00 1.0e+00 RP1-257A7.5
Taking other prescription medications 2.44 1 1 2.2 0.00 1.0e+00 ZNF652
Age when periods started (menarche) 1.16 1 0 0.0 0.00 1.0e+00 ZNF652
High blood pressure 7.89 3 2 4.4 0.00 1.0e+00 FES TCF21 ZNF652
Hayfever, allergic rhinitis or eczema 2.54 2 1 2.2 0.00 1.0e+00 FES ZNF652
Multivitamins +/- minerals 1.99 1 0 0.0 0.00 1.0e+00 ADAMTS7
Medication: Atenolol 7.76 2 1 2.2 0.00 1.0e+00 CDKN2B FES
Sitting height 1.17 4 1 2.2 -0.32 6.8e-01 ADAMTS7 FES SLC22A3 ZNF652
Chronic bronchitis/emphysema (father) 4.39 1 0 0.0 0.00 1.0e+00 ADAMTS7
High blood pressure (mother) 8.02 2 1 2.2 0.00 1.0e+00 FES RP1-257A7.5
Impedance of leg (left) 2.49 2 2 4.4 0.00 1.0e+00 FES ZNF652
Leg predicted mass (left) 1.05 2 0 0.0 0.00 1.0e+00 FES SLC22A3
Trunk fat mass 1.14 1 0 0.0 0.00 1.0e+00 SLC22A3
Number of incorrect matches in round 1.40 1 0 0.0 0.00 1.0e+00 FES
Past tobacco smoking 2.76 2 0 0.0 0.00 1.0e+00 CDKN2B-AS1 ZNF652
Alcohol usually taken with meals 2.51 2 0 0.0 0.00 1.0e+00 FES ZNF652
Heart attack 25.95 11 8 17.8 0.98 2.8e-07 ADAMTS7 CDKN2B CDKN2B-AS1 FES RP11-378J18.8 RP1-257A7.5 SLC22A1 SLC22A3 SORT1 TCF21 ZNF652
Allergy 3.43 2 1 2.2 0.00 1.0e+00 FES ZNF652
Medication: Ramipril 5.17 2 0 0.0 0.00 1.0e+00 FES ZNF652
Medication: Simvastatin 14.50 7 2 4.4 0.90 5.7e-03 CDKN2B CDKN2B-AS1 FES RP11-378J18.8 SLC22A1 SLC22A3 SORT1
Illnesses of siblings 3.78 2 1 2.2 0.00 1.0e+00 FES ZNF652
Weight 0.87 1 0 0.0 0.00 1.0e+00 SLC22A3
Impedance of arm (right) 1.64 2 1 2.2 0.00 1.0e+00 CDKN2B ZNF652
Arm fat percentage (right) 1.05 1 0 0.0 0.00 1.0e+00 SLC22A3
Trunk fat-free mass 0.91 2 0 0.0 0.00 1.0e+00 SLC22A3 SORT1
Hip circumference 1.22 2 1 2.2 0.00 1.0e+00 ADAMTS7 SLC22A3
Father's age at death 7.34 4 1 2.2 -1.00 2.3e-03 CDKN2B CDKN2B-AS1 FES SORT1
Number of live births 1.38 1 0 0.0 0.00 1.0e+00 FES
Pulse rate 2.92 2 1 2.2 0.00 1.0e+00 SLC22A1 TCF21
Asthma 3.44 2 1 2.2 0.00 1.0e+00 FES ZNF652
Medication: Ibuprofen (e.g. Nurofen) 3.82 2 1 2.2 0.00 1.0e+00 RP1-257A7.5 SLC22A3
Medication: Cholesterol lowering 21.78 8 3 6.7 0.89 3.1e-03 CDKN2B CDKN2B-AS1 FES RP11-378J18.8 SLC22A1 SLC22A3 SORT1 TCF21
Lung cancer (father) 4.71 1 0 0.0 0.00 1.0e+00 ADAMTS7
Illnesses of mother 6.30 3 1 2.2 0.00 1.0e+00 CDKN2B FES ZNF652
Pulse wave Arterial Stiffness index 3.87 2 0 0.0 0.00 1.0e+00 FES RP1-257A7.5
Impedance of arm (left) 1.56 1 1 2.2 0.00 1.0e+00 ZNF652
Arm fat mass (right) 0.95 1 0 0.0 0.00 1.0e+00 SLC22A3
Trunk predicted mass 0.89 2 0 0.0 0.00 1.0e+00 SLC22A3 SORT1
Standing height 1.14 3 3 6.7 0.00 1.0e+00 SLC22A3 SORT1 ZNF652
Breastfed as a baby 1.53 1 0 0.0 0.00 1.0e+00 FES
Hair/balding pattern: Pattern 4 1.12 1 0 0.0 0.00 1.0e+00 FES
Birth weight of first child 4.04 2 1 2.2 0.00 1.0e+00 FES TCF21
Peak expiratory flow (PEF) 1.59 1 1 2.2 0.00 1.0e+00 TCF21
Medication: Paracetamol 2.06 1 1 2.2 0.00 1.0e+00 RP1-257A7.5
Headache pain in last month 4.89 3 1 2.2 0.00 1.0e+00 FES RP1-257A7.5 ZNF652
Medication for cholesterol, blood pressure or diabetes 12.27 5 2 4.4 -0.91 3.3e-02 FES SLC22A1 SORT1 TCF21 ZNF652
Glaucoma (self-reported) 6.10 2 1 2.2 0.00 1.0e+00 CDKN2B CDKN2B-AS1
Medication: Amlodipine 4.29 2 1 2.2 0.00 1.0e+00 FES TCF21
Medication: Ventolin 100micrograms inhaler 2.11 1 0 0.0 0.00 1.0e+00 ZNF652
Birth weight 2.04 1 1 2.2 0.00 1.0e+00 FES
Chronic bronchitis/emphysema (mother) 2.76 1 0 0.0 0.00 1.0e+00 ADAMTS7
High blood pressure (siblings) 3.50 1 1 2.2 0.00 1.0e+00 FES
Forced vital capacity (FVC), Best measure 0.74 1 0 0.0 0.00 1.0e+00 TCF21
Body fat percentage 1.07 1 0 0.0 0.00 1.0e+00 SLC22A3
Leg fat percentage (right) 0.98 1 0 0.0 0.00 1.0e+00 RP11-378J18.8
Arm fat-free mass (right) 0.74 2 0 0.0 0.00 1.0e+00 SLC22A3 SORT1
Comparative body size at age 10 1.87 1 1 2.2 0.00 1.0e+00 ZNF652
Wheeze or whistling in the chest in last year 1.55 1 0 0.0 0.00 1.0e+00 ZNF652
Pulse wave peak to peak time 3.74 2 0 0.0 0.00 1.0e+00 FES RP1-257A7.5
Medication for pain relief, constipation, heartburn 3.27 2 0 0.0 0.00 1.0e+00 RP1-257A7.5 SORT1
Medication: Blood pressure 8.40 4 2 4.4 0.84 1.6e-01 FES SLC22A1 TCF21 ZNF652
Angina (self-reported) 33.85 11 10 22.2 1.00 2.9e-16 ADAMTS7 CDKN2B CDKN2B-AS1 FES RP11-378J18.8 RP1-257A7.5 SLC22A1 SLC22A3 SORT1 TCF21 ZNF652
Migraine (self-reported) 5.16 1 1 2.2 0.00 1.0e+00 RP1-257A7.5
Medication: Ibuprofen 4.06 2 1 2.2 0.00 1.0e+00 RP1-257A7.5 SLC22A3
Medication: Seretide 50 evohaler 2.58 1 0 0.0 0.00 1.0e+00 ZNF652
Mean time to correctly identify matches 1.66 1 0 0.0 0.00 1.0e+00 FES
Heart disease (mother) 16.40 8 3 6.7 0.96 3.7e-05 ADAMTS7 CDKN2B CDKN2B-AS1 FES RP11-378J18.8 RP1-257A7.5 SLC22A1 SLC22A3
Whole body fat mass 1.03 1 0 0.0 0.00 1.0e+00 SLC22A3
Leg fat mass (right) 0.80 1 0 0.0 0.00 1.0e+00 SLC22A3
Arm predicted mass (right) 0.77 2 0 0.0 0.00 1.0e+00 SLC22A3 SORT1
Pulse rate, automated reading 3.72 4 1 2.2 0.70 3.0e-01 RP11-378J18.8 RP1-257A7.5 SORT1 TCF21
Alcohol intake frequency. 1.87 1 0 0.0 0.00 1.0e+00 RP1-257A7.5
Comparative height size at age 10 1.07 3 0 0.0 0.00 1.0e+00 FES SLC22A3 SORT1
Overall health rating 2.27 1 1 2.2 0.00 1.0e+00 ZNF652
Chest pain or discomfort 3.88 1 0 0.0 0.00 1.0e+00 CDKN2B
Had major operations 3.22 1 0 0.0 0.00 1.0e+00 ZNF652
Medication: Aspirin 15.09 7 5 11.1 0.99 4.2e-05 CDKN2B CDKN2B-AS1 FES SLC22A1 SLC22A3 SORT1 TCF21
Hypertension (Self-reported) 8.11 4 2 4.4 0.87 1.3e-01 FES SLC22A3 TCF21 ZNF652
Illnesses of father: Heart disease 28.53 10 8 17.8 0.99 1.3e-08 ADAMTS7 CDKN2B CDKN2B-AS1 FES RP11-378J18.8 RP1-257A7.5 SLC22A1 SLC22A3 SORT1 TCF21
Smoking status: Previous 2.06 1 0 0.0 0.00 1.0e+00 CDKN2B-AS1
Whole body fat-free mass 0.94 3 0 0.0 0.00 1.0e+00 FES SLC22A3 SORT1
Leg fat-free mass (right) 1.11 3 0 0.0 0.00 1.0e+00 FES SLC22A3 SORT1
Handedness (chirality/laterality): Left-handed 1.93 1 0 0.0 0.00 1.0e+00 FES
Long-standing illness, disability or infirmity 2.55 2 0 0.0 0.00 1.0e+00 CDKN2B ZNF652
Diabetes diagnosed by doctor 1.33 1 0 0.0 0.00 1.0e+00 SLC22A3
Medication for cholesterol 6.70 4 2 4.4 -1.00 8.8e-04 FES SLC22A3 SORT1 ZNF652
Mineral and other dietary supplements 3.10 1 0 0.0 0.00 1.0e+00 FES
Breast cancer (self-reported) 2.67 1 0 0.0 0.00 1.0e+00 CDKN2B
Asthma (self-reported) 3.41 2 1 2.2 0.00 1.0e+00 FES ZNF652
Medication: Aspirin 15.56 7 5 11.1 0.99 4.5e-05 CDKN2B CDKN2B-AS1 FES SLC22A1 SLC22A3 SORT1 TCF21
Illnesses of father: None of the above (group 1) 10.34 4 2 4.4 -0.98 1.8e-02 CDKN2B CDKN2B-AS1 FES SLC22A3
Forced expiratory volume in 1-second (FEV1), predicted percentage 1.86 1 0 0.0 0.00 1.0e+00 ADAMTS7
Whole body water mass 0.91 3 0 0.0 0.00 1.0e+00 FES SLC22A3 SORT1
Leg predicted mass (right) 1.13 3 0 0.0 0.00 1.0e+00 FES SLC22A3 SORT1
Arm fat mass (left) 0.92 1 0 0.0 0.00 1.0e+00 SLC22A3
Number of self-reported non-cancer illnesses 3.96 1 1 2.2 0.00 1.0e+00 ZNF652
Mother's age at death 2.08 1 0 0.0 0.00 1.0e+00 SLC22A1
Eye problems/disorders: Glaucoma 7.27 2 2 4.4 0.00 1.0e+00 CDKN2B CDKN2B-AS1
Medication: Blood pressure 6.71 4 1 2.2 0.70 3.0e-01 ADAMTS7 FES SLC22A3 ZNF652
Supplements: Fish oil (including cod liver oil) 2.66 1 0 0.0 0.00 1.0e+00 SLC22A3
High cholesterol (Self-reported) 22.24 5 3 6.7 0.79 1.1e-01 FES RP11-378J18.8 SLC22A1 SLC22A3 SORT1
Medication: Bendroflumethiazide 5.52 3 1 2.2 0.00 1.0e+00 ADAMTS7 FES TCF21
Medication: Paracetamol 1.77 1 0 0.0 0.00 1.0e+00 RP1-257A7.5
Medication: Lisinopril 2.26 1 0 0.0 0.00 1.0e+00 FES
Medication: Atorvastatin 17.30 5 3 6.7 0.96 1.0e-02 CDKN2B CDKN2B-AS1 SLC22A1 SLC22A3 SORT1
Illnesses of father: High blood pressure 5.02 1 1 2.2 0.00 1.0e+00 FES
Ever smoked 2.40 2 0 0.0 0.00 1.0e+00 FES ZNF652
Basal metabolic rate 0.91 3 0 0.0 0.00 1.0e+00 FES SLC22A3 SORT1
Arm fat-free mass (left) 0.72 2 0 0.0 0.00 1.0e+00 SLC22A3 SORT1
Number of operations (self-reported) 1.79 1 0 0.0 0.00 1.0e+00 ZNF652
Risk taking 2.14 1 0 0.0 0.00 1.0e+00 FES
Age started oral contraceptive pill 2.31 2 0 0.0 0.00 1.0e+00 FES ZNF652
Diastolic blood pressure, automated reading 7.25 5 3 6.7 0.70 1.9e-01 ADAMTS7 CDKN2B CDKN2B-AS1 FES ZNF652
Vascular/heart problems diagnosed by doctor 10.24 5 3 6.7 -0.91 3.0e-02 CDKN2B FES SLC22A3 TCF21 ZNF652
Cholesterol lowering medication 12.58 4 2 4.4 0.88 1.2e-01 CDKN2B SLC22A1 SLC22A3 SORT1
Medication: Omeprazole (e.g. Zanprol) 1.52 1 0 0.0 0.00 1.0e+00 TCF21
Pain experienced in last month 1.59 1 0 0.0 0.00 1.0e+00 RP1-257A7.5
Basal cell carcinoma (self-reported) 3.09 1 0 0.0 0.00 1.0e+00 CDKN2B
Heart attack/myocardial infarction (self-reported) 26.15 11 8 17.8 0.98 3.4e-07 ADAMTS7 CDKN2B CDKN2B-AS1 FES RP11-378J18.8 RP1-257A7.5 SLC22A1 SLC22A3 SORT1 TCF21 ZNF652
Heart disease (siblings) 12.22 7 1 2.2 0.97 3.9e-04 ADAMTS7 CDKN2B-AS1 FES RP1-257A7.5 SLC22A1 SLC22A3 SORT1
Pack years of smoking 6.67 1 1 2.2 0.00 1.0e+00 ADAMTS7
Impedance of whole body 2.05 1 1 2.2 0.00 1.0e+00 ZNF652
Leg fat mass (left) 0.71 1 0 0.0 0.00 1.0e+00 SLC22A3
Arm predicted mass (left) 0.77 2 0 0.0 0.00 1.0e+00 SLC22A3 SORT1

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 0 0.000 1.3
GTEx Adipose Visceral Omentum 1 0.049 1.3
GTEx Adrenal Gland 0 0.000 1.3
GTEx Artery Aorta 2 0.067 1.4
GTEx Artery Coronary 0 0.000 1.3
GTEx Artery Tibial 3 0.080 1.4
GTEx Brain Caudate basal ganglia 0 0.000 1.3
GTEx Brain Cerebellar Hemisphere 1 0.067 1.3
GTEx Brain Cerebellum 0 0.000 1.3
GTEx Brain Cortex 0 0.000 1.4
GTEx Brain Frontal Cortex BA9 0 0.000 1.4
GTEx Brain Hippocampus 0 0.000 1.3
GTEx Brain Hypothalamus 0 0.000 1.2
GTEx Brain Nucleus accumbens basal ganglia 0 0.000 1.3
GTEx Brain Putamen basal ganglia 0 0.000 1.2
GTEx Breast Mammary Tissue 0 0.000 1.3
GTEx Breast Mammary Tissue (Male) 0 0.000 1.2
GTEx Breast Mammary Tissue (Female) 0 0.000 1.2
GTEx Cells EBV-transformed lymphocytes 1 0.070 1.4
GTEx Cells Transformed fibroblasts 1 0.024 1.3
GTEx Colon Sigmoid 0 0.000 1.2
GTEx Colon Transverse 0 0.000 1.3
GTEx Esophagus Gastroesophageal Junction 0 0.000 1.3
GTEx Esophagus Mucosa 1 0.030 1.3
GTEx Esophagus Muscularis 0 0.000 1.3
GTEx Heart Atrial Appendage 0 0.000 1.3
GTEx Heart Left Ventricle 0 0.000 1.3
GTEx Liver 1 0.139 1.4
GTEx Lung 1 0.035 1.3
GTEx Muscle Skeletal 1 0.035 1.3
GTEx Nerve Tibial 0 0.000 1.3
GTEx Ovary 0 0.000 1.3
GTEx Pancreas 0 0.000 1.3
GTEx Pituitary 0 0.000 1.3
GTEx Prostate 0 0.000 1.3
GTEx Skin Not Sun Exposed Suprapubic 0 0.000 1.3
GTEx Skin Sun Exposed Lower leg 1 0.027 1.4
GTEx Small Intestine Terminal Ileum 0 0.000 1.4
GTEx Spleen 0 0.000 1.3
GTEx Stomach 0 0.000 1.3
GTEx Testis 0 0.000 1.3
GTEx Thyroid 1 0.025 1.3
GTEx Uterus 0 0.000 1.3
GTEx Vagina 0 0.000 1.4
GTEx Whole Blood 1 0.050 1.3
METSIM Adipose 1 0.022 1.3
NTR Blood 0 0.000 1.3
ROSMAP Brain Pre-frontal Cortex 2 0.046 1.3
YFS Blood 1 0.022 1.3
CommonMind Brain Pre-frontal Cortex 5 0.093 1.4
The Cancer Genome Atlas Bladder Urothelial Carcinoma 2 0.121 1.4
The Cancer Genome Atlas Breast Invasive Carcinoma 3 0.068 1.3
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 1 0.091 1.4
The Cancer Genome Atlas Colon Adenocarcinoma 2 0.097 1.4
The Cancer Genome Atlas Esophageal Carcinoma 0 0.000 1.4
The Cancer Genome Atlas Glioblastoma Multiforme 1 0.098 1.3
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 1 0.037 1.4
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 1 0.024 1.3
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 2 0.098 1.4
The Cancer Genome Atlas Brain Lower Grade Glioma 1 0.023 1.3
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 2 0.181 1.4
The Cancer Genome Atlas Lung Adenocarcinoma 2 0.068 1.4
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 1 0.040 1.4
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 1 0.063 1.3
The Cancer Genome Atlas Pancreatic Adenocarcinoma 0 0.000 1.4
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 0 0.000 1.3
The Cancer Genome Atlas Prostate Adenocarcinoma 1 0.022 1.3
The Cancer Genome Atlas Rectum Adenocarcinoma 0 0.000 1.3
The Cancer Genome Atlas Soft Tissue Sarcoma 0 0.000 1.3
The Cancer Genome Atlas Skin Cutaneous Melanoma 0 0.000 1.4
The Cancer Genome Atlas Stomach Adenocarcinoma 1 0.059 1.4
The Cancer Genome Atlas Testicular Germ Cell Tumors 1 0.078 1.4
The Cancer Genome Atlas Thyroid Carcinoma 1 0.019 1.3
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 0 0.000 1.4